IOVANCE BIOTHERAPEUTICS, INC.
No SEC Form 4 filings for $IOVA in the last 30 days.
See all $IOVA insider activity →Iovance Biotherapeutics (IOVA) shares hit a 52-week high of $6.94 and last traded around $6.96. The article cites 12-month revenue of $325 million (up 35% YoY) and Q2 2026 results: adjusted loss of $0.11 per share vs $0.13 expected, and revenue of $99.31 million vs $87.12 expected, driven by Amtagvi sales.
Iovance Biotherapeutics (NASDAQ:IOVA) reported Q2 2026 revenue of $99.3M, up 66% YoY, driven by Amtagvi. Amtagvi revenue was $91M. Gross margin rose to 56%. Cash and investments were $304M, expected to fund operations into H2 2028. Full-year 2026 revenue guidance was $350M to $370M; management may update it in Q3.
Iovance Biotherapeutics (IOVA) reported Q2 results on Aug. 6. Revenue rose to $99.3 million, up 66% year over year, with Amtagvi (lifileucel) generating $91 million. Net loss narrowed to $47.3 million from $111.7 million. The FDA approved Amtagvi for unresectable or metastatic melanoma in early 2024.
Over the past 7 days, alphai's AI scored 3 news stories mentioning IOVA (IOVANCE BIOTHERAPEUTICS, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent IOVA coverage spans earnings, financial news and market movers.
The combination of a new 52-week high and an earnings beat on revenue and loss narrowing suggests improving fundamentals and supports near-term momentum.
Q2 results and 2026 revenue guidance plus manufacturing and trial updates create a near-term catalyst for IOVA positioning.
The earnings print and Amtagvi-driven growth are a near-term positive catalyst, supporting momentum and improving the path to profitability narrative.
The article frames IOVA as potentially undervalued versus a $18 fair-value estimate, anchored to the reaffirmed revenue range and improving losses.
New institutional ownership information may influence Iovance’s investor perception and liquidity, but the filing alone does not change fundamentals or governance control.
alphai scores every news story that mentions IOVA with an AI model for sentiment and relevance, and aggregates insider trades from IOVANCE BIOTHERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Iovance Biotherapeutics (IOVA) shares hit a 52-week high of $6.94 and last traded around $6.96. The article cites 12-month revenue of $325 million (up 35% YoY) and Q2 2026 results: adjusted loss of $0.11 per share vs $0.13 expected, and revenue of $99.31 million vs $87.12 expected, driven by Amtagvi sales.
2 min readIovance Biotherapeutics (NASDAQ:IOVA) reported Q2 2026 revenue of $99.3M, up 66% YoY, driven by Amtagvi. Amtagvi revenue was $91M. Gross margin rose to 56%. Cash and investments were $304M, expected to fund operations into H2 2028. Full-year 2026 revenue guidance was $350M to $370M; management may update it in Q3.
6 min readIovance Biotherapeutics (IOVA) reported Q2 results on Aug. 6. Revenue rose to $99.3 million, up 66% year over year, with Amtagvi (lifileucel) generating $91 million. Net loss narrowed to $47.3 million from $111.7 million. The FDA approved Amtagvi for unresectable or metastatic melanoma in early 2024.
4 min readSimply Wall St reports Iovance Biotherapeutics (IOVA) released Q2 2026 results with higher revenue and a smaller net loss, and reaffirmed full-year revenue guidance of US$350 million to US$370 million. The article cites a fair value estimate of $18 versus a $6.34 close and discusses valuation multiples and ongoing losses of US$289.517 million.
6 min readState Street Corporation (NYSE: STT) filed a Schedule 13G reporting beneficial ownership of 24,478,268 shares of Iovance Biotherapeutics, representing 5.5% of the class. The filing attributes shared voting power of 23,483,868 shares and shared dispositive power of 24,478,268 shares, with no sole voting or dispositive power.
4 min readIovance Biotherapeutics (IOVA) reported Q2 2026 EPS loss of $0.11, narrower than the Zacks Consensus ($0.17). Revenue rose 66% to $99.3M, beating consensus $87.3M and guidance $86M-$88M. Amtagvi sales were $90.7M, up 68% YoY, while Proleukin was $8.6M. Shares jumped 43% after results; guidance review planned for Q3.
6 min readBiotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
3 min readIovance Biotherapeutics (NASDAQ:IOVA) shares rose sharply after the company reported Q2 revenue of $99.3 million, up 66% year over year, driven by Amtagvi. Amtagvi generated about $91 million, up 68% year over year. Net loss narrowed to $47.3 million. The company cited additional marketing approvals, including Australia, and a UK expedited review.
6 min readIovance Biotherapeutics (IOVA) shares rose about 37% after the company reported a narrower second-quarter loss, supported by strong revenue growth, according to the company. The stock was around $5.97 on Thursday, up 37.44%, after opening near $5.95 and reaching about $6.39.
2 min readIovance Biotherapeutics (NASDAQ: IOVA) reported record 2Q26 revenue of about $99.3M, up 66% YoY, with gross margin of 56%, driven by U.S. Amtagvi demand. U.S. Amtagvi revenue was about $91M. The company is reviewing FY26 revenue guidance of $350M-$370M and said FDA granted Fast Track designation for lifileucel in soft tissue sarcomas.
6 min read
